STAT

Opinion: ‘Benign sexism’ intrudes at a meeting of the world’s brightest minds

Even in the wake of the #MeToo moment, we still find ourselves confronting sexism in what we perceive to be the most progressive, sophisticated spaces.

It’s 2018. We’re in the wake of the #MeToo moment. Increased reporting is exposing rampant sexism in medicine, media, and beyond. Women are now more empowered than ever to speak up in response to bias and harassment. One could think we’ve come a long way.

And yet, for all our expressed outrage at widespread sexual harassment and our newfound “wokeness” about gender equity, we still find ourselves confronting sexism in what we perceive to be the most progressive, sophisticated spaces.

That was driven home where two of us (E.M. and N.N.) were honored to be part of a panel discussing the growing epidemic of clinician burnout in the United

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks